Journal of Bone Oncology

Papers
(The H4-Index of Journal of Bone Oncology is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
MAT2A inhibits the ferroptosis in osteosarcoma progression regulated by miR-26b-5p164
#15. Single-cell discovery and multi-omic characterization of therapeutic targets in multiple myeloma39
Lipid metabolic reprogramming and associated ferroptosis in osteosarcoma: From molecular mechanisms to potential targets32
Non-invasive MRI biomarkers for assessment of neoadjuvant chemotherapy response in osteosarcoma: Current techniques and clinical perspectives32
Single Photon Emission Computed Tomography/X-ray Computed Tomography-based radiomics analysis for diagnosis of bone metastases in patients with breast cancer31
Senescence in the bone marrow microenvironment: A driver in development of therapy-related myeloid neoplasms26
Macrophage heterogeneity in bone metastasis22
Real-life use of bone-targeting agents for bone metastases in France between 2009 and 2018: Results of the OPTIMOS study21
From bimodal to unimodal: The transformed incidence of osteosarcoma in the United States21
Chinese expert consensus on the diagnosis and clinical management of medication-related osteonecrosis of the jaw20
Postoperative outcomes of subaxial cervical spine metastasis: Comparison among the anterior, posterior, and combined approaches20
Predicting lung metastasis in high-grade osteosarcoma: The role of computed tomography angiography (CTA) signs with a focus on vascular wrapping and the intratumoral vascular network19
State-of-the-art of minimally invasive treatments of bone metastases19
Radiomics model based on MRI to differentiate spinal multiple myeloma from metastases: A two-center study19
Demethylzeylasteral inhibits proliferation and metastasis of osteosarcoma cells by modulating the PI3K/AKT/Autophagy pathways19
#1. Acid ceramidase (ASAH1) is a key mediator of drug resistance in relapsed/refractory multiple myeloma18
A multicenter, randomized, double-blind trial comparing LY01011, a biosimilar, with denosumab (Xgeva®) in patients with bone metastasis from solid tumors18
Association of androgen receptor and tumour-infiltrating lymphocytes with bone recurrence in triple-negative breast cancer18
Questionable indication for postoperative radiotherapy after surgery for metastases of the major long bones: A single-centre cohort study of 552 fractures/526 patients18
Preoperative prediction of high-grade osteosarcoma response to neoadjuvant therapy based on a plain CT radiomics model: A dual-center study18
0.29072403907776